Implanet Reports 4Q16 and 2016 Revenue
Implanet posted 2016 revenue of €7.8MM (~US $8.6MM), +18% vs. 2015, with of 4Q16 revenue of €2.2MM (~US $2.4MM), +36% vs. 4Q15.
ORTHOWORLD estimates 2016 segment sales and growth vs. 2015 on an as-reported basis, as follows.
- Knee Reconstruction ~$3.1MM, -2.8%
- Arthroscopy/Soft Tissue Repair ~$1.1MM, -3.6%
- Spine ~$4.5MM, +45.3%
For 2016 in spine, the company's largest revenue stream, Implanet reported geographic growth of +70% in the U.S., +33% in France and +21% Rest of World.
For 2016, the company sold a total of 7,001 JAZZ spinal implants, +25% from 2015, comprising 1,450 in the U.S., 3,552 in France and 1,999 in the Rest of World.
At year-end in its direct markets of France and the U.S., Implanet reports having 127 surgeon users of JAZZ technology, +55% vs. 2015. Of those users, 69 were based in the U.S. (+60% vs. 2015) and 58 in France (+49% vs. 2015).
Implanet reports that knee recon and arthroscopy/soft tissue repair revenue was impacted by macroeconomic difficulties in Brazil.
Thus far in 2017, the company has reported the granting of a European patent for the JAZZ implant universal tensioning system.
Sources: Implanet, ORTHOWORLD Inc.